氯吡格雷片联合阿司匹林肠溶片治疗急性冠状动脉综合征患者对IMA、sCD40L水平的影响

Effects of Clopidogrel Tablets Combined with Aspirin Enteric-coated Tablets on IMA and sCD40L Levels in Patients with Acute Coronary Syndrome

目的探讨氯吡格雷片联合阿司匹林肠溶片治疗急性冠状动脉综合征患者对IMA、sCD40L水平的影响。方法便利选取该院2020年3月-2021年3月收治的86例急性冠状动脉综合征患者,采取数表法随机分为研究组和对照组,各43例。给予对照组患者单纯阿司匹林肠溶片治疗,研究组在对照组基础上加服氯吡格雷片。比较两组患者临床疗效、IMA水平、sCD40L水平及不良反应发生率差异。结果研究组治疗总有效率为90.70%,比对照组72.09%高,差异有统计学意义(P<0.05)。治疗前,两组患者IMA(91.87±10.02)、(92.03±9.88)U/mL,sCD40L(468.21±65.23)、(457.87±62.14)×10^(9)/L水平对比差异无统计学意义(P>0.05);治疗后,两组患者IMA、sCD40L水平均明显下降,研究组(78.23±11.27)U/mL、(353.47±68.64)×10^(9)/L降幅较对照组(84.34±10.54)U/mL、(408.72±67.19)×10^(9)/L更为显著,差异有统计学意义(P<0.05)。研究组患者腹痛腹泻、恶心呕吐、药物性皮疹及出血倾向等不良事件的发生率为2.33%、6.98%、9.30%、4.65%,对照组不良事件发生率依次为6.89%、11.63%、6.98%、6.98%,差异无统计学意义(P>0.05)。结论氯吡格雷片联合阿司匹林肠溶片治疗急性冠状动脉综合征的疗效显著,可有效降低血清中IMA、sCD40L水平,且不会增加不良反应发生率。

Objective To explore the effect of clopidogrel tablets combined with aspirin enteric-coated tablets on the IMA and sCD40L levels in patients with acute coronary syndrome.Methods It was convenient to select of 86 patients with acute coronary syndrome admitted to the hospital from March 2020 to March 2021 and were randomly divided into a study group and a control group,with 43 cases in each group.Patients in the control group were treated with aspirin enteric-coated tablets alone,and the study group was given clopidogrel tablets in addition to the control group.The clinical efficacy,IMA level,sCD40L level and the incidence of adverse reactions between the two groups were compared.Results The total effective rate of treatment in the study group was 90.70%higher than 72.09%in the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in the levels of IMA(91.87±10.02)U/mL,(92.03±9.88)U/mL,sCD40L(468.21±65.23)×10^(9)/L,(457.87±62.14)×10^(9)/L between the two groups of patients(P>0.05);after treatment,the levels of IMA and sCD40L of the two groups of patients decreased significantly,the study group(78.23±11.27)U/mL,(353.47±68.64)×10^(9)/L decreased more significantly than the control group(84.34±10.54)U/mL,(408.72±67.19)×109/L,the difference was statistically significant(P<0.05).The incidence of adverse events such as abdominal pain,diarrhea,nausea and vomiting,drug-induced rash,and bleeding tendency in the study group were 2.33%,6.98%,9.30%,and 4.65%,and the incidence of adverse events in the control group was 6.89%,11.63%,6.98%,6.98%,there was no statistically significant difference between groups(P>0.05).Conclusion Clopidogrel tablets combined with aspirin enteric-coated tablets are effective in treating acute coronary syndromes.It can effectively reduce the levels of IMA and sCD40L in the serum without increasing the incidence of adverse reactions.